Press Release Aug 20 2020
Filed with NSE · · 4 pages · English
Summary by 6ix AI
This product is the first approved allogeneic cell therapy globally for this condition and aims to provide affordable treatment options for patients in India. Cipla will market and distribute Stempeucel® in India, leveraging its extensive distribution network.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Cipla
Later from Cipla
- Press Release Sep 25 2020
- Press Release Oct 12 2020
- Press Release Oct 20 2020
- Press Release Oct 28 2020
- Press Release Nov 06 2020
Follow Cipla into a list and get an email when it puts out news.
Follow Cipla